The National Cancer Institute (NCI) invites applications for Research Units (RUs) within the Pancreatic Cancer Detection Consortium (PCDC).
The program supports multidisciplinary research focused on the early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of precursor lesions to identify individuals at high risk of progression to pancreatic cancer. Research will support the development and validation of molecular, fluid-based, imaging, and integrated approaches for early detection and risk assessment. Pasted text
Eligibility Criteria
- Eligible applicants include public and private institutions of higher education.
- Nonprofit organizations are eligible.
- For-profit organizations and small businesses are eligible.
- State, county, city, township, special district, and federally recognized tribal governments are eligible.
- Foreign organizations are not eligible to apply.
- Non-domestic components of U.S. organizations are not eligible.
- Any individual with the appropriate skills, knowledge, and resources may serve as the Program Director/Principal Investigator.
Funding Details
- Funding: Up to $600,000 in direct costs per year
- Duration: Up to 5 years
- Funding mechanism: U01 Cooperative Agreement
- No cost sharing is required.
Deadline
- Next application deadline: February 5, 2027
- Additional deadlines: June 5, 2027; October 5, 2027; February 5, 2028; June 5, 2028; October 5, 2028; February 5, 2029; June 5, 2029; October 5, 2029
- Application time: 5:00 PM local time of the applicant organization
- Open date: January 5, 2027
- Expiration date: November 6, 2029.
Further Information
- The U01 cooperative agreement involves substantial NIH/NCI scientific and programmatic involvement.
- Applicants must use NIH ASSIST, Grants.gov Workspace, or an institutional system-to-system solution for submission.
- Official Funding Opportunity: NIH/NCI — PAR-28-056
- Grants.gov: Grants.gov — PAR-28-056